Skip to content

KPV

Tags: KPV, Anti-inflammatory, Immune Modulation, Bowel Health

Quick Summary

KPV is a potent anti-inflammatory tripeptide derived from α-MSH that inhibits NF-κB signaling to reduce inflammatory cytokines. Researched for inflammatory bowel disease, skin conditions, and systemic immune modulation with an excellent safety profile.

Quick Facts

  • Typical Dose: 200–500 mcg (0.2–0.5 mL at 1 mg/mL)
  • How often: 1–2 times daily (depending on condition severity)
  • Route: Injectable — Subcutaneous (abdomen preferred for gut issues; thigh, upper arm)
  • Cycle: 4–8 weeks
  • Storage: Refrigerate 2–8°C after reconstitution

Overview

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). This small peptide exhibits anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH. KPV has shown promise for inflammatory bowel diseases, skin conditions, and immune modulation through its ability to penetrate cells and interact with inflammatory signaling pathways.

Key Benefits

  • Systemic anti-inflammatory effects
  • Immune modulation
  • Potential for autoimmune and inflammatory gut/skin conditions

Mechanism of action

Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling, reducing transcription of TNF-α, IL-6 and other inflammatory cytokines.

Research indications

  • Inflammation: Most Effective
  • Gut Health: Effective
  • Immune Function: Moderate

Research protocols

Goal Dose Frequency Route
General Anti-Inflammatory 200–300 mcg Once daily Subcutaneous
Active Inflammation 250 mcg Twice daily Subcutaneous
Autoimmune Support 500 mcg Once daily Subcutaneous
Acute Flare-ups 500 mcg Twice daily for 1 week then reduce Subcutaneous

Timing: KPV can be dosed flexibly. For gut issues, some prefer morning dosing. For systemic inflammation, split doses may provide better coverage.

Interactions

Compatible / Complementary

  • BPC-157 — Synergistic
  • TB-500 — Compatible
  • LL-37 — Synergistic
  • Thymosin Alpha-1 — Compatible
  • GHK-Cu — Synergistic for skin

Monitor

  • Melanotan II — Use caution

Avoid

  • None documented; standard precautions with immunosuppressive agents apply

How to reconstitute

  1. Clean vial top with alcohol pad
  2. Add 1 mL bacteriostatic water to 1 mg vial (creates 1000 mcg/mL)
  3. For easier dosing: Add 2 mL to 1 mg vial (creates 500 mcg/mL)
  4. Gently swirl to mix - KPV dissolves easily
  5. Solution should be clear and colorless
  6. Label with concentration and date

Important: Always use bacteriostatic water (BAC). Sterile technique is essential.

Quality Indicators

Positive Signs

  • High purity (>98%) confirmed by certificate of analysis
  • Clear and colorless solution after reconstitution
  • Proper pH 5.5–7 for optimal stability
  • Small, stable tripeptide structure relative to larger peptides

Warning Signs

  • Visible cloudiness or particles indicate contamination or degradation — do not use
  • Yellow coloration indicates oxidation and loss of potency — do not use
  • Low purity (<98%) unsuitable for inflammatory condition use

What to expect

  • Day 1–3: Subtle reduction in inflammation, improved energy
  • Week 1: Noticeable decrease in inflammatory symptoms
  • Week 2–3: Improved gut function, reduced pain/swelling
  • Week 4: Significant improvement in target condition
  • Week 6–8: Sustained anti-inflammatory benefits, improved quality of life

Side effects & safety

  • Excellent safety profile with minimal side effects
  • Does not cause immunosuppression like steroids
  • No melanin production or tanning effects
  • May temporarily reduce inflammation-related symptoms
  • Monitor for signs of infection (rare)
  • Generally well-tolerated even at higher doses

References

KPV in Inflammatory Bowel Disease Models (2019)

  • Animal model | Oral and injection | 14 days | Colitis model

Research demonstrating KPV's efficacy in inflammatory bowel disease animal models.

Anti-Inflammatory Mechanisms of KPV (2020)

  • In vitro | Various concentrations | Cell culture studies

Investigation of KPV's molecular mechanisms for inhibiting inflammatory signaling pathways.

KPV for Psoriasis and Dermatitis (2021)

  • Human cells + Animal model | Topical application | 4 weeks

Study examining KPV's effects on skin inflammatory conditions including psoriasis and dermatitis.